Welcome to our dedicated page for Beroni Group news (Ticker: BNIGF), a resource for investors and traders seeking the latest updates and insights on Beroni Group stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Beroni Group's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Beroni Group's position in the market.
Beroni Group (OTCQX: BNIGF) has signed a Memorandum of Understanding with tella, Inc. to collaborate on cancer immunotherapy. The partnership aims to leverage both companies' resources for clinical trials in dendritic cell vaccine therapy and gamma delta T cell therapies in Japan and China. tella has previously treated approximately 12,200 patients with its vaccine therapy across 28 institutions in Japan. The collaboration is expected to enhance treatment access for cancer patients and improve clinical trial generalizability.
Beroni Group has received export authorization for its SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method), enhancing its ability to combat COVID-19. This test kit, CE certified for EU markets since December 2020, requires only a nasopharyngeal swab and provides results within 10 minutes. Clinical results show a sensitivity of 98.36% and specificity of 99.19% for nasopharyngeal sampling. Chairman Jacky Zhang highlighted the kit's importance before vaccination and the company’s readiness to distribute it globally.
Beroni Group (OTCQX: BNIGF) has successfully completed a majority acquisition of PENAO Pty Ltd, securing a 60% shareholding. PENAO focuses on developing the anti-cancer drug PENAO, which has shown promising efficacy and safety in clinical trials. The drug has a faster accumulation rate in cancer cells compared to its predecessor, potentially offering improved treatment options for advanced solid tumors. This acquisition aligns with Beroni's strategy to enhance its oncology portfolio and meet the growing demand for novel cancer therapies.
Beroni Group (OTCQX: BNIGF) announced the successful completion of a SARS-CoV-2 pseudovirus neutralization assay in partnership with GenScript Biotech. This study identifies effective nanobodies capable of neutralizing the virus. Results showed one nanobody achieved over 90% signal reduction, while three others yielded 50% inhibition of pseudovirus infection. Beroni aims to develop aerosolized nanobody treatments for COVID-19, leveraging its research to advance preclinical studies. The company remains committed to finding optimal nanobodies for both detection and treatment solutions against the coronavirus.